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Background. Erythropoietin (EPO) is a neuroprotective agent utilized in stroke patients. This pilot study represents the ﬁrst
randomized trial of EPO in traumatic brain injury (TBI) patients. Methods. Adult, blunt trauma patients with evidence of TBI
were randomized to EPO or placebo within 6 hours of injury. Baseline and daily serum S-100B and Neuron Speciﬁc Enolase (NSE)
levels were measured. Results. TBI was worse in the EPO (n = 11) group compared to placebo patients (n = 5). The use of EPO
did not impact NSE (P = .89) or S100 B (P = .53) levels compared to placebo. Conclusions. At the dose used, EPO did not reduce
neuronal cell death compared to placebo; however, TBI severity was worse in the EPO group while levels of NSE and S100-B were
similar to the less injured placebo group making it diﬃcult to rule out a treatment eﬀect. A larger, balanced study is necessary to
conﬁrm a potential treatment eﬀect.
1.Introduction
Despite injury prevention eﬀorts, severe head injury is
estimated to occur at a rate of 200 per 100,000 people in
the United States [1]. Close to 100,000 head injured patients
suﬀerpermanentdisability ordeath eachyear.The economic
consequences of this are equally impressive with 30 million
workdays lost and a societal cost of 83.5 billion dollars per
year [1, 2].
Traumatic brain injury follows a well-recognized pattern
beginning with the primary injury due to the traumatic
event. The neuronal loss from this event is irrecoverable;
however,regionssurroundingthesedamagedsitesaresubject
to alterations in cerebral blood ﬂow regulation, edema,
inﬂammation, apoptosis, and ischemia. Furthermore, these
regions may have increased metabolic demands, thereby
increasing the disparity between oxygen requirements and
supply. These vulnerable areas, known as the ischemic
penumbra, reﬂect regions of the brain prone to secondary
brain injury [3, 4].
As a result, current management principles of the head
injured focus upon prevention of secondary brain injury in
order to maximize the neurologic outcome. The strategies
employed reﬂect the need to provide well-oxygenated blood
ﬂow to these vulnerable regions of the brain [1, 4–7]. These
strategies, however, do not primarily manipulate neuronal
cellular activity and substrate requirements, but instead deal
only with maintenance of adequate substrate supply.
Recently, several investigations have demonstrated that
EPO has time-dependent neuroprotective eﬀects in animal
models independent of its role in erythropoiesis [8–14]. The
mechanisms by which EPO exerts its eﬀects on neuronal
cells are not clearly understood, but evidence suggests that
it mediates cerebral vasoconstriction, glutamate toxicity,
neuronal antioxidant activity, endothelial cell apoptosis, and
nitric oxide release [8–15]. Several lines of evidence indicate
that EPO, administered peripherally, may cross the blood
brain barrier through a speciﬁc transport mechanism which
may be up-regulated during cerebral hypoxia [16–18]. Taken
together, these studies suggest a therapeutic role for EPO in
head injured patients during their resuscitation. The safety
and eﬃcacy of EPO in TBI patients has yet to be assessed
clinically. We, therefore, proposed a randomized, double-
blinded, placebo-controlled, pilot study to determine if EPO,2 Critical Care Research and Practice
given to moderate traumatic brain injury (TBI) patients
during the resuscitative phase, would be safe and could lead
toameasurablereductioninneuronalcelldeathasmeasured
by neuron-speciﬁc cell markers.
2. Methods
This was a randomized, double-blind, placebo-controlled
single-center trial in which patients either received EPO or
saline placebo of equal volume. All blunt trauma patients
≥18 years of age with an admission GCS < 13 and evidence
of traumatic brain injury (TBI) on CT were eligible for this
IRB approved study. After obtaining informed consent from
the family, patients were randomized to receive EPO (40,000
Units IV) or placebo administered within 6 hours of the time
of injury. The primary outcome measure was S-100B and
NSE levels in patients receiving EPO were compared to those
receiving placebo. The sample size estimate was based upon
an anticipated reduction of 25% in S-100B levels with EPO
treatment compared to placebo. The sample size required to
detect such a diﬀerence with type II error of 0.9 and type I
error of 0.05, using a two-sided binomial hypothesis, was 43
patients per group. Assuming a 25% drop out rate for early
nontraumatic brain injury-related mortality and/or refused
consent from family members after enrollment, the planned
enrollment was 108 patients (54 per group) into the study.
The study only enrolled 23 patients due to the fact that the
primary investigator had moved to another institution prior
to study completion.
Patients had baseline (day of injury) and daily serum
S-100B and NSE levels measured until 5 days after injury.
Demographic and clinical data were obtained including
age, gender, head AIS, ISS, admission and ICU GCS, daily
mean ICP and CPP (when ICP was monitored), number
and nature of ICP lowering interventions, and daily mean
PaCO2. Secondary outcome measures included ICU LOS,
GCS at ICU discharge, and in-hospital mortality. CT scans
were independently reviewed by a radiologist (blinded to
the randomization) using a standardized technique for
quantifyingheadinjuryseveritythatcorrelateswithoutcome
[19].
Blood samples were collected by venipuncture upon
admission and approximately every 24 hours thereafter
until 5 days post injury. Samples were allowed to clot
for 20–30 minutes at room temperature and centrifuged
at 800–1000RPM for 10 minutes and stored at −18
◦C
for analysis. S-100B and NSE were analyzed in duplicate
using a monoclonal 2-site immunoluminometric assay kit
(Santeg 100 and NSE proliﬁgen; AB Santeg Medical). Sample
and luminescence-labeled anti-S-100B or anti-NSE were
added to the antibody-coated tube and then incubated.
Unbound material was removed by washing. Tracer-S-100B
or NSE complex bound to the tube wall was detected
by light reaction (425nm) produced by the reaction as
measured using a liminometer. The light signal, measured
in relative light units, was therefore directly proportional to
the amount of NSE or S-100 present in the standard and
sample.
16 enrollees
7 exlusions (4 EPO, 3 Placebo)
reason: outside 6-hour window
23 eligible subjects
randomized
32 patients meeting
inclusion criteria
9r e f u s e dc o n s e n t
Figure 1: Study population.
Baseline patient characteristics were compared using
Studentt-testforcontinuousvariablesandchi-squaretesting
for categorical variables. A multivariate repeated measures
analysis of covariance (ANCOVA) was performed to ascer-
tain the eﬀect of EPO on NSE and S-100B serum levels
between groups over time while adjusting for diﬀerences
in head injury severity. For all analyses, α was set at 0.05.
Analyses were conducted using Stata Statistical Software
(release 9.0, Stata Corp, College Station, Tex).
3. Results
A total of 23 patients were initially randomized with 7
patients dropping out before receiving the study agent
leaving 16 patients (EPO n = 11, placebo n = 5) for
subsequent analysis. The 7 dropouts were patients who were
initially randomized but never received the study agent or
placebo because they were found to be outside of the six-
hour inclusion criteria by the time the agent was available
(Figure 1).
The groups were similar in terms of demographics, and
overall injury severity; however, CT rating of the head injury
severity showed that the EPO group had signiﬁcantly more
severe injury at baseline despite randomization (Table 1).
The EPO group was also found to have a lower admission
GCS compared to the placebo group (5.4 versus 8.3, resp.,
P = .1)despitethefactthattheheadabbreviatedinjuryscore
was similar for both groups.
Daily mean S-100B and NSE levels were initially elevated
and then declined signiﬁcantly (P<. 0001) in both groups
over the ﬁrst three days but remained detectable throughout
the 5-day measurement period (Figures 2(a) and 2(b),
Table 2). The use of EPO did not signiﬁcantly impact NSE
(P = .89) or S-100B (P = .53) levels compared to placebo
over the 5 day period despite adjustment for head injuryCritical Care Research and Practice 3
Table 1: Characteristics of patients receiving erythropoietin or
placebo.
Characteristic (SD) EPO Placebo P-value
(n = 11) (n = 5)
Age 35 (19) 40 (26) NS
Male 73% 60% NS
Admit GCS 4.7 (3.3) 8.8 (5.3) .04
Admit SBP 130 (33) 115 (26) NS
Admit HR 91 (18) 78 (18) NS
ICU GCS 11 (3.6) 9.8 (4.9) NS
Sedation on arrival 73% 40% NS
ISS 27 (8.4) 21.6 (8.4) NS
Head AIS 4 (0.6) 3.8 (0.4) NS
Midline shift (mm) 2.0 (3.4) 0 (0) P = .12
EAH grade 6.0 (8.1) 0.3 (0.6) P = .07
SDH grade 4.2 (7.3) 0 (0) P = .12
EDH grade 1.8 (5.3) 0.3 (0.6) NS
ICH grade 11.5 (12.7) 5.6 (9.0) NS
SAH grade 3.2 (1.0) 3 (1.4) NS
GCS: Glascow Coma Score, SBP: Systolic Blood Pressure, HR: Heart Rate,
ICU GCS: ﬁrst recorded GCS in the ICU, ISS: Injury Severity Score, AIS:
Abbreviated Injury Severity Score, EAH: Extra-axial Hemorrhage, SDH:
Subdural Hemorrhage, EDH: Epidural Hemorrhage, ICH: Intracranial
Hemorrhage, SAH: Subarachnoid Hemorrhage.
Table 2: Daily NSE and S-100B levels by study group.
NSE S-100B
Day EPO Placebo EPO Placebo
Admission 34.4 (20.9) 24.9 (21.0) 0.087 (0.04) 0.094 (0.05)
1 20.0 (9.9) 16.4 (6.4) 0.035 (0.01) 0.041 (0.03)
2 20.3 (16.4) 9.4 (4.0) 0.025 (0.009) 0.031 (0.02)
3 9.5 (10.5) 7.8 (7.6) 0.017 (0.006) 0.016 (0.004)
4 8.9 (7.3) 11.2 (13.4) 0.016 (0.005) 0.016 (0.004)
5 10.8 (9.2) 4.1 (1.8) 0.016 (0.005) 0.016 (0.003)
severity. Mean daily ICP values were not diﬀerent between
the two groups (Figure 3). There were two in-hospital deaths
in the EPO group and none in the placebo group (P = NS).
One patient died from his head injury and the other died
from hypoxia from ARDS. One episode of DVT occurred in
the placebo group and none in the EPO group (P = NS).
MeanmaximumICPlevelsweresimilarforeachofthe5days
between the two groups. ICU length of stay, was shorter for
the EPO group by a mean of 2 days, with and without the
two deaths, but this did not reach statistical signiﬁcance.
4. Discussion
This preliminary analysis did not demonstrate a reduction in
neuronal cell death as determined by serum markers when
EPO was administered at a dose of 40,000 units within 6
hours of injury. Secondary outcomes of death, length of stay
and Glascow outcome scores also did not diﬀer with the
treatment.
Placebo
EPO
Injury 1 2 3 4 5
Time (days)
0
10
20
30
40
[
N
S
E
]
(
μ
g
/
L
)
(a)
Placebo
EPO
Injury 1 2 3 4 5
Time (days)
0
0.02
0.04
0.06
0.08
0.1
[
S
1
0
0
B
]
(
μ
g
/
m
L
)
(b)
Figure 2: (a) NSE Serum levels in patients receiving EPO or
Placebo. (b) S-100B Serum levels in patients receiving EPO or
Placebo.
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Figure 3: Mean daily ICP by study group.4 Critical Care Research and Practice
Several limitations in this study aﬀect our ability to draw
any strong conclusions from the absence of an eﬀect. First,
the study is underpowered for its primary outcome of NSE
and S-100B levels as a result of premature study cessation
secondary to reasons not associated with the study itself. As
ar e s u l t ,al a c ko ft r e a t m e n te ﬀect may not be secondary
to lack of eﬃcacy but because of inadequate sample size.
Second, while NSE and S-100B have been correlated with
the presence and severity of head injury, they may not be
suﬃciently sensitive to correlate with any beneﬁcial neuro-
protective eﬀects that EPO may be having. Recently, several
investigations have identiﬁed lipid membrane peroxidation
as a major contributor to blood brain barrier breakdown
and hence neuronal death [20–22]. Furthermore, these
byproducts of lipid peroxidation are vasoreactive leading
to cerebrovasoconstriction, further compromising neuronal
cell longevity [22]. F2-isoprostaglandin is one such marker
of lipid peroxidation and has been used to quantify the
extent of traumatic brain injury and response to antioxidant
therapies, such as progesterone. In fact, CSF levels of F2-
isoprostane have been quantiﬁed as a useful marker of TBI
in children demonstrating dramatic elevations compared to
control groups [20, 23]. In adults the degree of oxidative
stress appears to diﬀer by gender and age after TBI as
determined by diﬀerences in the levels of F2-ispoprostanes
betweenmalesandfemalesandolderversusyoungerpatients
[24]. These data indicate that the isoprostanes are a useful
marker of TBI severity and are modulated by therapies
that reduce oxidative stress after TBI. Future studies should
therefore make use of this biomarker of neuronal injury to
quantify treatment eﬀects.
Several studies in the stroke literature using EPO as a
neuroprotective agent have examined functional outcomes
far beyond the short-term laboratory markers examined in
this pilot study. The 5-day follow up in this trial was chosen
based upon previous trials in the stroke and TBI literature
which identiﬁed that NSE and S-100B levels reach baseline
levels within 3–5 days of injury.
As this is a preliminary study, the ideal dose to achieve a
treatment eﬀect is not yet known. In stroke patients higher
doses of EPO, given over longer duration, have proven
to be neuroprotective [25, 26]. Ehrenreich et al. studied
the safety and eﬃcacy of EPO in stroke patients using a
dose of 33,000IU given intravenously daily for three days.
Their study demonstrated that CSF concentrations of EPO
increased 60–100-fold compared to the placebo group and
there was a correlation between EPO use and improved
outcomes with smaller infarct size [26]. Subsequent studies
in TBI patients will likely need to use similar doses to ensure
adequate CSF penetration for a beneﬁcial eﬀect to be clearly
observed.
Any study of TBI which includes polytrauma patients
may suﬀer from confounding secondary to the inﬂuence
of other injuries on outcomes. In this study, we included
patients with extracranial injuries which clearly has an
impact on mortality and neurologic recovery. The severity
of the extracranial injuries was not signiﬁcantly diﬀerent
between the two groups which would reduce the degree
of confounding. Furthermore, since the primary outcome
of the study was early postinjury neurospeciﬁc proteins
the eﬀect of extracranial injuries would likely be minimal
unless these injuries contributed signiﬁcantly to the ability to
provide adequate cerebral perfusion or signiﬁcant hypoxia.
As is shown in Table 1, there was no signiﬁcant hypotension
in either groups suggesting that the injuries were not likely a
signiﬁcant cause of early cerebral hypoxia.
While this study failed to show eﬃcacy, this should
not deter further research regarding the use of EPO in
TBI patients. Despite the randomization process, the small
sample size leads to a disproportionately greater degree of
head injury in the EPO group relative to the placebo group.
In all of the radiographic measures of head injury severity
assessed,theEPOpatientsweremoreseverelyinjured.Again,
the small sample size contributes to the lack of a statistical
relationship being observed but one cannot overlook the fact
thattheradiographicappearancediﬀeredintermsofseverity
between the two groups in a clinically meaningful way. It
is noteworthy that, in spite of this diﬀerence in head injury
severity, EPO patients’ NSE and S-100B levels fell as rapidly
and to the same degree as the placebo group. It is therefore
possible that, had these patients not received EPO, the degree
of neuronal death observed may have been greater and may
have been associated with higher NSE and S-100B levels
than what we observed. This is purely speculation, however,
and a larger trial with a dose-ﬁnding strategy is needed to
determine if EPO is neuroprotective in TBI patients. This
study demonstrates the safety of its use and the need for
higher dosing in future studies.
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